NU 2019-067

INVENTORS  
Herbert Y. Meltzer

SHORT DESCRIPTION
Repurposing bumetaide to treat cognitive deficits in schizophrenia syndrome.

ABSTRACT
Cognitive deficits associated with schizophrenia syndrome are the components that contribute most to a low quality of life. While current pharmacological treatments have beneficial effects on treating delusions and hallucinations, the fail to address the cognitive deficits. Northwestern researchers have demonstrated that oral administration of the FDA approved drug bumetanide, is effective in preventing and treating the cognitive deficits as well as other symptoms. Additionally, this could have benefits in the treatment of many other neuopsychiatric disorders if combined with other drugs. Overall, we believe that this will lead to improved overall function and less frequent relapses in patients with schizophrenia syndrome.

APPLICATIONS

• Treatment of schizophrenia syndrome and neuropsychiatric disorders.

ADVANTAGES

• Effective treatment of the negative cognitive deficits in schizophrenia syndrome.

IP STATUS
Issued US Patent No. 11,666,547